DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC0

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06467357?term=destiny-biliary&rank=2

Contact name

Laura Morse Cucci

Clinical trials study type

Oncology - Gastrointestinal

Clinical trials trial status

Open to Accrual

IRB number

2346030

Principal investigator

Gang Chen, MD, PhD

Clinical trials study number

G2506

Phone

443-849-3122

Clinical trials title (full)

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC00001)